Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Baldini

Showing results (111-120 of 151) with videos related to

Pageof 16
Sort By:
European Journal of Haematology|November 21, 2008
Considerations in the treatment of multiple myeloma: a consensus statement from Italian expertsFrancesca Patriarca, Maria T Petrucci, Sara Bringhen, et al.
British Journal of Haematology|November 30, 2010
Immunogenetics features and genomic lesions in splenic marginal zone lymphomaAndrea Rinaldi, Francesco Forconi, Luca Arcaini, et al.
Haematologica|November 26, 2013
Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana LinfomiMichele Merli, Carlo Visco, Michele Spina, et al.
The Lancet. Haematology|October 4, 2023
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trialMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Blood|November 29, 2002
Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissueEmanuele Zucca, Annarita Conconi, Ennio Pedrinis, et al.
European Journal of Haematology|November 26, 2009
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMAFortunato Morabito, Massimo Gentile, Stefania Ciolli, et al.
Haematologica|June 1, 2010
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphomaSilvia Zibellini, Daniela Capello, Francesco Forconi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2013
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana LinfomiUmberto Vitolo, Marco Ladetto, Carola Boccomini, et al.
Thrombosis and Haemostasis|April 28, 2017
Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL)Roberto Mario Santi, Manuela Ceccarelli, Elisa Bernocco, et al.
American Journal of Hematology|August 6, 2019
Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) networkMarzia Varettoni, Emanuela Boveri, Silvia Zibellini, et al.
Pageof 16

Showing results (111-120 of 151) with videos related to

Sort By:
Pageof 16
European Journal of Haematology|November 21, 2008
Considerations in the treatment of multiple myeloma: a consensus statement from Italian expertsFrancesca Patriarca, Maria T Petrucci, Sara Bringhen, et al.
British Journal of Haematology|November 30, 2010
Immunogenetics features and genomic lesions in splenic marginal zone lymphomaAndrea Rinaldi, Francesco Forconi, Luca Arcaini, et al.
Haematologica|November 26, 2013
Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana LinfomiMichele Merli, Carlo Visco, Michele Spina, et al.
The Lancet. Haematology|October 4, 2023
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trialMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Blood|November 29, 2002
Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissueEmanuele Zucca, Annarita Conconi, Ennio Pedrinis, et al.
European Journal of Haematology|November 26, 2009
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMAFortunato Morabito, Massimo Gentile, Stefania Ciolli, et al.
Haematologica|June 1, 2010
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphomaSilvia Zibellini, Daniela Capello, Francesco Forconi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2013
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana LinfomiUmberto Vitolo, Marco Ladetto, Carola Boccomini, et al.
Thrombosis and Haemostasis|April 28, 2017
Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL)Roberto Mario Santi, Manuela Ceccarelli, Elisa Bernocco, et al.
American Journal of Hematology|August 6, 2019
Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) networkMarzia Varettoni, Emanuela Boveri, Silvia Zibellini, et al.
Pageof 16